MDF takes its role as an advocate for the myotonic dystrophy community very seriously; we are committed to increasing visibility and understanding of DM, improving the quality of life of people living with this disease, and doing our part to accelerate research progress toward treatments and a cure for DM.
The Myotonic Dystrophy Foundation turned 5 this year! It was a notable milestone for a young patient organization, and one that saw enormous growth and advancement in a number of key areas,
A generic cardiovascular drug called mexiletine, initially developed to treat heart rhythm abnormalities, appears to hold some potential for treating muscle stiffness and other symptoms of non-dystrophic myotonias (NDMs),
You spoke and we listened. MDF conducted a post-conference survey in September, capturing participant feedback to inform future conference programs. The results of the 2012 MDF Annual Conference survey were illuminating.
If you attended this year’s MDF Annual Conference, you heard about it there. If you didn’t, read on to learn more about MDF’s newest initiative.